Coriolan Lebreton
Coriolan Lebreton is an expert in Oncology at Institut Bergonié (France). As of October 2026, ScienceLeadR ranks Coriolan Lebreton in the top 1% of experts worldwide for Ovarian Neoplasms, Adnexal Diseases and Gonadal Disorders. Coriolan Lebreton has authored 76 publications, the most recent in 2026, and is an investigator in 37 clinical trials, 15 of them ongoing. SLR score: 767 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Gynecology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2018 - 2026
Number : 76
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Clinical outcomes and prognostic factors in advanced high-grade platinum-resistant ovarian carcinoma: evidence from the ESME real-world cancer database. PMID 42660771 — progression-free survival, paclitaxel, ovary, genital neoplasms, female, doxorubicin, neoplasms, multiple chronic conditions, bevacizumab, drug therapy, ovarian neoplasms, prognosis, chemotherapy | Int J Gynecol Cancer | 2026 | 0 |
| Long‑Term Effectiveness and Safety of Doravirine‑Based Antiretroviral Regimens in Virologically Suppressed People with HIV: The French Dat'AIDS Cohort. PMID 42613399 — safety, rna-directed dna polymerase, hiv, therapeutics, reverse transcriptase inhibitors | Infect Dis Ther | 2026 | 0 |
| Complementary intra- and extracellular AGR2 activities support epithelial ovarian cancer cell aggressiveness. PMID 42575981 — oncogenes, cells, stress, physiological, ovary, neoplasms, ovarian neoplasms, carcinoma, ovarian epithelial | Oncogene | 2026 | 0 |
| Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial. PMID 42385345 — cytoreduction surgical procedures, progression-free survival, ovary, neoplasms, nucleosomes, drug therapy, biomarkers, chemotherapy, adjuvant, ovarian neoplasms, chemotherapy | Transl Oncol | 2026 | 0 |
| Avelumab Plus Methotrexate for Gestational Trophoblastic Tumors: The TROPHAMET Phase 1/2 Nonrandomized Clinical Trial. PMID 42275082 — pregnancy, safety, trophoblastic neoplasms, neoplasms, drug therapy, therapeutics, non-randomized controlled trials as topic, methotrexate, chemotherapy | JAMA Oncol | 2026 | 0 |
Clinical Studies 37
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
15 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| A clinical study of sacituzumab tirumotecan for cervical cancer (MK 2870 036) 2025-521514-26-00 — safety, uterine cervical neoplasms, neoplasms, bevacizumab, maintenance, respect, therapeutics | Phase 3 | Recruiting | 2026 |
| A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK 2870 022) 2023-508015-23-00 — safety, ovary, neoplasms, bevacizumab, drug therapy, maintenance, ovarian neoplasms, therapeutics, chemotherapy | Phase 3 | Not yet recruiting | 2025 |
| A clinical study of sacituzumab tirumotecan and pembrolizumab in people with endometrial cancer (MK 2870 033) 2024-519331-42-00 — dna mismatch repair, safety, neoplasms, maintenance, respect, therapeutics, endometrial neoplasms, carcinoma | Phase 3 | Recruiting | 2025 |
| First time in human (FTIH) study to investigate the safety and preliminary activity of GSK5533524 alone or in combination in adult participants with advanced solid tumors 2025-524165-25-00 — safety, neoplasms | Phase 1 | Recruiting | 2026 |
| A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab vs Chemotherapy plus Pembrolizumab as First Line Treatment of HER2 Expressing (IHC 3 2 ) Mismatch Repair Proficient (pMMR) Endometrial Cancer 2023-508056-19-00 — dna mismatch repair, neoplasms, drug therapy, therapeutics, trastuzumab, endometrial neoplasms, chemotherapy | Phase 3 | Recruiting | 2025 |
LeadR Networks
Main global connection map